Regeneron Pharmaceuticals Inc. Watch

from 8-K 137 pages Credit Agreement Dated as of December 19, 2022 Among Regeneron Pharmaceuticals, Inc. Regeneron Healthcare Solutions, Inc. Regeneron Genetics Center LLC the Other Subsidiary Borrowers Party Hereto the Lenders Party Hereto and Jpmorgan Chase Bank, N.A. as Administrative Agent Bank of America, N.A. and U.S. Bank National Association as Co-Syndication Agents Citibank, N.A., Fifth Third Bank, National Association, Goldman Sachs Bank USA and Barclays Bank PLC as Co-Documentation Agents and Jpmorgan Chase Bank, N.A., Bofa Securities, Inc. and U.S. Bank National Association as Joint Bookrunners and Joint Lead Arrangers

from 10-K 17 pages Amendment No. 1 Dated as of November 11, 2021 to Credit Agreement Dated as of December 14, 2018

from 10-Q 6 pages Amendment No. 1 to the Credit Agreement

from 8-K 143 pages Credit Agreement Dated as of May 25, 2020 Among Regeneron Pharmaceuticals, Inc. the Lenders Party Hereto Goldman Sachs Bank USA as Administrative Agent Goldman Sachs Bank USA as Sole Bookrunner and Sole Lead Arranger

from 8-K 172 pages Credit Agreement Dated as of December 14, 2018 Among Regeneron Pharmaceuticals, Inc. Regeneron Healthcare Solutions, Inc. Regeneron Genetics Center LLC the Other Subsidiary Borrowers Party Hereto the Lenders Party Hereto Jpmorgan Chase Bank, N.A. as Administrative Agent Bank of America, N.A. and U.S. Bank National Association as Co-Syndication Agents and Citibank, N.A., Fifth Third Bank, Mufg Bank, Ltd. and Barclays Bank PLC as Co-Documentation Agents Jpmorgan Chase Bank, N.A., Merrill Lynch, Pierce, Fenner & Smith Incorporated, and U.S. Bank National Association as Joint Bookrunners and Joint Lead Arrangers

from 10-K 3 pages Credit Suisse Capital LLC (“Cs”) and Regeneron Pharmaceuticals, Inc. (“Issuer”) Are Parties to a Warrant Transaction Pursuant to a November 13, 2013 Assignment by Credit Suisse International, an Affiliate of Dealer, to Cs of Such Warrant Transaction. the Warrant Transaction Is Evidenced by the Master Terms and Conditions for Base Warrants Issued by Regeneron Pharmaceuticals, Inc. Dated as of October 18, 2011, Supplemented by the Written Confirmation Dated as of October 18, 2011 and Amended by the Amendment Dated as of May 14, 2014, the Second Amendment Dated as of November 18, 2014, the Third Amendment Dated as of November 24, 2014 and the Fourth Amendment Dated as of November 15, 2015 (As So Amended, the “Confirmation”). Terms Used Herein but Are Not Otherwise Defined Shall Have Meanings Assigned to Them in the Confirmation. 1. Termination. Effective Upon Payment of the Termination Payment on the Payment Date (Each as Defined Below), the Number of Warrants for Each Component of the Transaction Shall Be Reduced to Zero, and the Confirmation Shall Be of No Further Force and Effect. 2. Termination Payment. in Consideration of the Termination of the Transaction as Provided Herein, Issuer Agrees to Pay to Cs on the Payment Date the Amount in Usd Set Forth Below (The “Termination Payment”). Termination Payment Amount: Usd 12,873,684.18 Payment Date: November 18, 2016

from 10-K 11 pages Credit Suisse Capital LLC (“Cs”) and Regeneron Pharmaceuticals, Inc. (“Issuer”) Are Parties to a Warrant Transaction Pursuant to a November 13, 2013 Assignment by Credit Suisse International, an Affiliate of Dealer, to Cs of Such Warrant Transaction. the Warrant Transaction Is Evidenced by the Master Terms and Conditions for Base Warrants Issued by Regeneron Pharmaceuticals, Inc. Dated as of October 18, 2011, Supplemented by the Written Confirmation Dated as of October 18, 2011 and Amended by the Amendment, Dated as of May 14, 2014, the Second Amendment, Dated as of November 18, 2014, and the Third Amendment, Dated as of November 24, 2014 (As So Amended, the “Confirmation”). Terms Used Herein but Are Not Otherwise Defined Shall Have Meanings Assigned to Them in the Confirmation

from 8-K 173 pages Credit Agreement Dated as of March 19, 2015 Among Regeneron Pharmaceuticals, Inc. Regeneron Healthcare Solutions, Inc. Regeneron Genetics Center LLC Regeneron International Regeneron Ireland Holdings Regeneron Ireland Regeneron Capital International B.V. the Other Subsidiary Borrowers Party Hereto the Lenders Party Hereto Jpmorgan Chase Bank, N.A. as Administrative Agent Bank of America, N.A. and U.S. Bank National Association as Co-Syndication Agents and Barclays Bank PLC, Citibank, N.A., Credit Suisse AG, Cayman Islands Branch, Fifth Third Bank and Morgan Stanley Mufg Loan Partners, LLC as Co-Documentation Agents J.P. Morgan Securities LLC, Merrill Lynch, Pierce, Fenner & Smith Incorporated, and U.S. Bank National Association as Joint Bookrunners and Joint Lead Arrangers

from 10-K 5 pages Credit Suisse Capital LLC (“Cs”) and Regeneron Pharmaceuticals, Inc. (“Issuer”) Are Parties to a Warrant Transaction Pursuant to a November 13, 2013 Assignment by Credit Suisse International, an Affiliate of Dealer, to Cs of Such Warrant Transaction. the Warrant Transaction Is Evidenced by the Master Terms and Conditions for Base Warrants Issued by Regeneron Pharmaceuticals, Inc. Dated as of October 18, 2011, Supplemented by the Written Confirmation Dated as of October 18, 2011 (The “Confirmation”) and Amended by the Amendments Dated as of May 14, 2014 and Dated as of November 19, 2014. Terms Used Herein but Are Not Otherwise Defined Shall Have Meanings Assigned to Them in the Warrant Confirmation. Upon the Effectiveness of This Amendment, All References in the Confirmation to the “Number of Warrants” Will Be Deemed to Be to the Number of Warrants as Amended Hereby and All References in the Confirmation to the “Transaction” Will Be Deemed to Be to the Transaction as Amended Hereby

from 10-K 5 pages Credit Suisse Capital LLC (“Cs”) and Regeneron Pharmaceuticals, Inc. (“Issuer”) Are Parties to a Warrant Transaction Pursuant to a November 13, 2013 Assignment by Credit Suisse International, an Affiliate of Dealer, to Cs of Such Warrant Transaction. the Warrant Transaction Is Evidenced by the Master Terms and Conditions for Base Warrants Issued by Regeneron Pharmaceuticals, Inc. Dated as of October 18, 2011, Supplemented by the Written Confirmation Dated as of October 18, 2011 (The “Confirmation”) and Amended by the Amendment Dated as of May 14, 2014. Terms Used Herein but Are Not Otherwise Defined Shall Have Meanings Assigned to Them in the Warrant Confirmation. Upon the Effectiveness of This Amendment, All References in the Confirmation to the “Number of Warrants” Will Be Deemed to Be to the Number of Warrants as Amended Hereby and All References in the Confirmation to the “Transaction” Will Be Deemed to Be to the Transaction as Amended Hereby

from 10-Q 5 pages Amendment, Dated as of May 14, 2014, to the Master Terms and Conditions for Warrants, Dated as of October 18, 2011, as Supplemented by a Confirmation Dated October 18, 2011, Between Credit Suisse Capital LLC (As Assignee of Credit Suisse International) and the Registrant

from 8-K 26 pages Master Terms and Conditions for Base Warrants Issued by Regeneron Pharmaceuticals, Inc

from 8-K 26 pages Master Terms and Conditions for Convertible Bond Hedging Transactions Between Credit Suisse International and Regeneron Pharmaceuticals, Inc